Study title: S2CQ30 A multicentre placebo-controlled study on the efficacy and safety of oral sumatriptan (100mg) in the treatment of migraine in adolescents.
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Nervous System Diseases [C10] | |||||
| Brands: Please see report | |||||
| MAH holders: Please see report | |||||
| Assessment: | |||||
| Active substance: SUMATRIPTAN | |||||
| ATC code: N02CC01 | |||||
| Document link: Study S2CQ30(SUM9291)-Sumatriptan-Imigranxlsx.xls | |||||
| Document date: 2011-10-20 | |||||
| Study number: SUM9291 | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | - | Y | |